Skip to NavigationSkip to content

sma

Protesters in Manchester call on NICE to approve Biogen's $750,000 drug Spinraza

Image Credit: Juliux | Manchester Town Hall

Protesters in Manchester have called on the National Institute of Health and Care Excellence (NICE), to overturn their rejection of the Spinal Muscular Atrophy (SMA) treatment Spinraza, after the public body chose not to approve the orphan drug for use on the NHS due “to uncertainties over its long-term effectiveness and its extremely high cost.”

Roche buys French biotech for €470 million

Roche image

Roche is buying France-based biotech Trophos in a deal worth up to €470 million in order to gain access to its promising Phase II drug olesoxime.

Trophos is developing olesoxime (TRO19622) for spinal muscular atrophy (SMA) – which is a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches